Abstract 511P
Background
The AsianmCRCRegistry is a prospective, open-label, multicentre data collection registry aimed to identify the most significant survival trends amongst Asian patients with metastatic colorectal cancer (mCRC).
Methods
A total of 843 mCRC patients were enrolled in the registry from 31 centres across 8 Asian countries from 06 January 2013 to 09 February 2017. Of these, 214 underwent liver resection.
Results
A total of 67.76% (n=145/214) patients underwent limited hepatectomy and 32.24 % (n=69/214) patients underwent major hepatectomy. Log-rank test on Kaplan Meier curves showed that 5-year overall survival (OS) was significantly higher for patients presenting with a colon diagnosis vs metastatic diagnosis (63% vs 30%; P=0.012), in patients with 1-3 metastases vs >3 metastases (74% vs 23%; P<0.0001), size of metastases <50 mm vs ≥50 mm (42% vs 28%; P=0.013), presence of concomitant extrahepatic disease vs absence (4-year OS was 77% vs 19%; P<0.0001), initial resectability vs unresectability (77% vs 47%; P=0.071), metachronous vs synchronous metastases (69% vs 26%; P<0.0001), unilateral vs bilateral localization (63% vs 19%; P<0.0001), response to last pre-operative chemotherapy (3-yr OS was 100% for CR and for SD, 90% for PR and 59% for disease progression; P=0.048), liver-curative intent at outset vs not (4-yr OS was 72% vs 21%; P=0.0002) and globally-curative intent at outset vs not(76% vs 34%; P=0.0002). Among patients who had targeted biologics as the last line of treatment prior to R0 resection, 75.86% (n=22/29) had PR, 10.34% (n=3/29) had either no change or disease progression and 3.25% (n=1/29) had CR. All patients who received cetuximab prior to R0 resection (n=14) had PR. A total of 42.68% patients receiving cetuximab+chemotherapy underwent R0R1 resection compared with 35.77% patients receiving bevacizumab+chemotherapy. 62.70% (n=153/214) of patients did not have any recurrence after hepatectomy. At last follow-up, 32.24% (n=69/214) of patients were alive and disease-free. Grade 1 adverse effects (AEs) were experienced by 14.29% of patients, 4.08% had grade 2 AEs, 4.08% had grade 3b AEs, & 2.04% had grade 4a AEs.
Conclusions
This study expands our understanding of real-world survival patterns of Asian mCRC patients undergoing hepatectomy.
Clinical trial identification
Editorial acknowledgement
Medical writing support provided by Dr. Pratishtha B Chaudhari from WriterMD Medical Writing Consultancy.
Legal entity responsible for the study
Dr. Catherine Teh, Makati Medical Center, Makati.
Funding
Merck Pte Ltd.
Disclosure
J. Huang: Full/Part-time employment: Merck Pte Ltd. All other authors have declared no conflicts of interest.